Return to Medscape coverage of: 25th Annual San Antonio Breast Cancer Symposium

Print this Activity for Offline ReferenceInstructions on Taking Medscape CME
25th Annual San Antonio Breast Cancer Symposium
Maximizing Bone Density in Patients With Breast Cancer
December 11 - 14, 2002, San Antonio, Texas

Writer: Emma Hitt, PhD

This activity is not sanctioned by, nor a part of, the 25th Annual San Antonio Breast Cancer Symposium.


Contents
Adjuvant hormonal therapies for breast cancer, particularly nonsteroidal aromatase inhibitors, can cause loss of bone mineral density. Zoledronate, a high-potency third-generation bisphosphonate, can help prevent bone loss and fractures. Studies suggest that zoledronate given in conjunction with adjuvant hormonal therapies for breast cancer can help eliminate this side effect. In addition, in patients with bone metastases, zoledronate has been shown to reduce the number of skeletal-related events, such as pathologic fracture and spinal cord compression.

Researchers at the 25th Annual San Antonio Breast Cancer Symposium presented the latest data on the use of zoledronate to maximize bone density in patients with breast cancer.
Use of Zoledronate in Patients With Breast Cancer
Emma Hitt, PhD

 
Legal Disclaimer
The materials presented here were prepared by independent authors under the editorial supervision of Medscape, and do not represent a publication of the San Antonio Breast Cancer Symposium. These materials and the related activity are not sanctioned by the San Antonio Breast Cancer Symposium or the commercial supporter of the conference, and do not constitute an official part of that conference.
The material presented here does not reflect the views of Medical Education Collaborative, Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing medical education activity.
Copyright © 2002 Medscape.

 
Astra Zeneca, Aventis, Genentech, Novartis

Related Resources
Clinical articles on this topic
All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.